1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Immuron Limited

Immuron Limited

IMC.AX
Immuron LimitedAU flagAustralian Securities Exchange
0.04
AUD
+0.00
- -
10.06MMarket Cap
Immuron Limited
IMC.AX
(Australian Securities Exchange)

Recent

price

0.04

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.05
0.02
0.04
0.01
0.02
0.01
0.01
0.01
0.01
0.02
0.01
- -
- -
0.01
0.02
0.03
Revenue per Share
-0.2
-0.23
-0.18
-0.28
-0.06
-0.04
-0.09
-0.06
-0.02
-0.03
-0.02
-0.04
-0.01
-0.02
-0.03
-0.02
Basic EPS, GAAP
-0.24
-0.17
-0.2
-0.16
-0.06
-0.04
-0.07
-0.07
-0.03
-0.01
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.31
0.1
0.09
-0.08
0.14
0.04
0.04
0.04
0.04
0.02
0.03
0.1
0.09
0.07
0.04
0.03
Book Value per Share
0.2
0.02
0.05
-0.04
0.16
0.04
0.06
0.06
0.06
0.05
0.03
0.12
0.1
0.09
0.06
0.03
Tangible Book Value per Share
9
11
12
13
42
75
76
106
134
145
176
221
228
228
228
231
Basic Weighted Avg Shares
- -
- -
- -
- -
1
1
1
1
2
2
3
- -
1
2
5
7
Sales/Revenue/Turnover
-490.26
-1,350.44
-735.61
-2,164.35
-259.63
-269.95
-651.02
-454.62
-166.21
-194.54
-120.9
-5,455.98
-407.4
-188.76
-106.38
-73.51
Operating Margin (%)
- -
- -
- -
1
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-2
-3
-2
-4
-3
-3
-7
-7
-3
-5
-3
-8
-3
-4
-7
-5
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-412.61
-1,212.98
-511.68
-2,363.27
-243.7
-268.54
-706.12
-487.33
-166.51
-195.04
-116.23
-5,751.61
-373.01
-209.81
-141.49
-71.58
Profit Margin (%)
2
- -
1
1
7
3
5
7
6
5
4
25
22
18
12
8
Working Capital
- -
- -
1
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
3
2
2
- -
7
3
5
7
8
7
6
26
23
20
13
8
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-126.22
-201.53
- -
- -
-60.4
-252.24
-196.75
-61.76
-104.83
-77.43
-62.25
-13.45
-20.81
-53.53
-65.34
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
33.45%
52.25%
-36.51%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
33.01%
42.3%
-24.81%
Sales/Revenue/Turnover
79.32%
137.37%
48.63%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
5
2025
- -
- -
- -
- -
7
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.03
2025
- -
- -
- -
- -
-0.02
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Evaxion Biotech A/S (EVAX)
Forma Therapeutics Holdings, Inc. (FMTX)
Acticor Biotech SAS (ALACT.PA)
Qrons Inc. (QRON)
Samsrita Labs Ltd. (SAMSRITA.BO)
OncoZenge AB (publ) (ONCOZ.ST)
Business
Immuron Limited (ASX:IMC; NASDAQ:IMRN) is an Australia-based biopharmaceutical company focused on the research, development, and commercialization of orally delivered targeted polyclonal antibodies derived from hyper-immune bovine colostrum for the prevention and treatment of enteric diseases and gastrointestinal disorders. The company offers commercial products including Travelan®, an over-the-counter medicine listed on the Australian Register of Therapeutic Goods (AUST L 106709) to reduce the risk of travellers' diarrhoea, minor gastrointestinal disorders, and antimicrobial exposure; Protectyn® (AUST L 231001), an immune supplement supporting healthy digestive function and liver health sold through practitioners in Australia; and ProIBS®, a clinically proven medicine for the relief of irritable bowel syndrome symptoms such as abdominal pain, bloating, and bowel irregularities. Its pipeline includes drug candidates such as Travelan (IMM-124E) in Phase II clinical trials for travellers' diarrhoea prevention with topline results expected in October 2025, IMM-529 in Phase II for recurrent Clostridioides difficile infections with an FDA Investigational New Drug application planned for August 2025, and IMM-986 in preclinical development for Vancomycin-resistant enterococci. Immuron operates in the biopharmaceutical industry with segments in research and development as well as hyper-immune products, targeting consumer health, military, and clinical markets in Australia, the United States, Canada, New Zealand, and through global partnerships. Founded in 1994 and formerly known as Anadis Limited until a name change in December 2008, the company is headquartered at 62 Lygon Street, Carlton South, Victoria, Australia. Recent developments include an exclusive distribution agreement with Calmino Group AB in March 2025 for ProIBS® launch in Australia and New Zealand pharmacies in Q1 2026; a new funded research agreement in August 2024 with the U.S. Naval Medical Research Command and Walter Reed Army Institute of Research to develop enhanced bovine colostrum formulations targeting Campylobacter, enterotoxigenic Escherichia coli, and Shigella pathogens; completion of recruitment for the Travelan Phase II study; strong sales growth projecting over A$7 million for FY2025 versus A$4.9 million in FY2024; and a partnership with InvestorHub announced in August 2025 to enhance investor communications.